Peptides with blood coagulation activity and their uses

Abstract

The present invention relates to a peptide having a novel sequence that has the property of being gelled depending on pH conditions, and since the peptide can induce blood coagulation, a composition containing the peptide can be usefully used for inducing hemostasis.

Description

[Technical field]

[0001] The present invention relates to novel peptides capable of inducing blood coagulation and uses thereof. [Background technology]

[0002] The vascular system plays an important role in transporting various nutrients and oxygen and carbon dioxide within animals, and blood and body fluids are exchanged between the blood vessels and tissues. However, when damage occurs to the skin tissue or blood vessels, blood and body fluids may leak out. If such bleeding is excessive, oxygen cannot be transported normally, which may lead to death. Therefore, methods of stopping bleeding have been developed to reduce bleeding.

[0003] The body has a system that autonomously induces blood coagulation, and blood cells are entangled with thrombin formed through an enzyme reaction and fibrin fibers produced from it to form a thrombus or clot, which inhibits the outflow of blood and body fluid components, thereby causing hemostasis. However, when excessive bleeding occurs due to a deep and large wound, the body's coagulation system alone may not be sufficient to stop the bleeding, and there is a great need to control the excessive bleeding that inevitably accompanies surgical operations, so that there is always a high demand for methods for effectively stopping the bleeding and substances having hemostatic activity.

[0004] Conventionally, chitosan, collagen, starch, beeswax, etc. have been used as ingredients of products used for hemostasis, and these are manufactured and applied in the form of powder, sponge, sheet, gel, etc. In Korean Patent Publication No. 2018-0027126, a composition containing a cross-linked hyaluronic acid derivative matrix was used to induce a hemostatic effect.

[0005] However, hemostatic preparations must be made of ingredients that are harmless to the body and must not cause side effects such as hemolysis, since they are basically applied to the site of injury or wound. Conventional hemostatic products using chitosan, polymers, etc., which have been developed as medical devices, have only a small hemostatic effect and have the problem that the residues must be decomposed or discharged from the body after application, and the residues may induce an inflammatory reaction. In addition, conventional biological pharmaceutical preparations with a blood coagulation mechanism have the disadvantages that they are not easy to manufacture, transport, or store because they are made of ingredients derived from the body, and they require a thawing process before use or must be used after mixing the first and second agents, which takes a long time to apply and is therefore not very convenient to use. Therefore, there is a need to develop a peptide preparation for promoting blood coagulation that has excellent manufacturing and storage stability and excellent hemostatic effect, and is synthesized using amino acid components that are components of the body. Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide a peptide that can be gelled under specific conditions and used to induce blood coagulation. Another object of the present invention is to provide a composition capable of effectively inducing hemostasis using such peptides. Another object of the present invention is to provide a method for hemostasis using the composition. [Means for solving the problem]

[0007] To achieve the above object, one aspect of the present invention provides a peptide having pH-dependent gelation properties, comprising the amino acid sequence of SEQ ID NO:1. Another aspect of the present invention provides a composition for inducing hemostasis, comprising the peptide. Another aspect of the invention provides a method of stopping bleeding comprising the step of applying the composition to the site of bleeding in an animal where bleeding has occurred. Effect of the Invention

[0008] The peptide provided in the present invention has a characteristic of gelling by itself under neutral pH conditions. Specifically, the peptide can gel and form aggregates under specific pH conditions, and thus, when the peptide or a composition containing the peptide is applied to blood or a body fluid, gelation of the peptide can proceed according to the pH conditions in the blood. The peptide aggregates with blood cells, or the nanofiber structure formed by the gelation of the peptide surrounds blood cells and blood components other than blood cells to form a mass, thereby causing precipitation or obstructing the flow or outflow of blood, thereby inducing hemostasis.

[0009] The peptide of the present invention and a composition containing the same have a similar level of blood coagulation-inducing activity as conventional commercially available hemostatic agents, are characterized by an excellent effect of shortening the time required for hemostasis, and do not induce hemolysis, so that they can be usefully used for inducing hemostasis.

[0010] In particular, while gelation does not proceed under acidic conditions and the composition may take the form of a liquid or sol, the peptide and composition of the present invention have fluidity by maintaining an acidic pH condition before actually applying to blood or body fluids, and therefore may exhibit properties more suitable for storage and application. Furthermore, when applied to blood or body fluids, gelation proceeds due to the neutral pH, and the composition has the advantage of effectively exerting a hemostatic effect at the bleeding site.

[0011] In addition, since the peptide of the present invention and the composition containing the same are made of amino acid components that constitute the body, there is an advantage that there is little possibility of side effects or problems with decomposition / excretion when applied to the body, and therefore there is a low possibility of inflammatory reactions. Furthermore, compared to conventional hemostatic preparations, there are advantages in that they are easy to manufacture and have excellent storage stability.

[0012] However, the effects of the present invention are not limited to those mentioned above, and other effects not mentioned will be clearly understood by those skilled in the art from the following description. [Brief description of the drawings]

[0013] [Figure 1] 1 is a graph showing the kcps value of light scattering intensity and particle size of the peptide of the present invention as a function of pH. [Diagram 2] 1 is a graph showing the optical density (OD 600) of a solution containing a peptide of the present invention depending on the salt (NaCl) concentration, and a photograph showing the morphology of the solution depending on the salt concentration. [Diagram 3] 1 is a photograph showing a comparison of the difference in the degree of gelation exhibited by different concentrations of the peptide of the present invention. [Figure 4] 1 shows the results of a hemagglutination test in which compositions containing the peptide of the present invention were mixed with a suspension of red blood cells collected from rats at different concentrations. The circled areas show the experimental results of the concentrations at which blood cells did not precipitate but started to form clots. [Diagram 5] 1 is a photograph showing the results of a blood coagulation test performed using a composition containing the peptide of the present invention, showing that blood coagulation occurred after 13 seconds. [Figure 6] This is the result of a coagulation test using a composition containing the peptide of the present invention, and the optical density of the supernatant of the centrifuged sample was measured and compared. The relative values ​​are shown based on the value of the negative control group (DW) treated with distilled water, and the groups treated with Greenplast Q and RADA16 peptide preparation were used as the control groups. [Figure 7]The results of an animal experiment on the hemostatic effect of a composition containing the peptide of the present invention are shown in the following figures: photographs of the bleeding site, bleeding loss, and bleeding time for a control group with no treatment (No Treatment), a control group with Greenplast treatment (Greenplast Q), and groups treated with the peptide of the present invention at concentrations of 1% and 2.5%. For the control group with no treatment, the bleeding loss was measured 90 seconds after the start of bleeding. [Figure 8] This is a graph showing the results of an animal experiment on the hemostatic effect of a composition containing the peptide of the present invention, comparing the bleeding time of an untreated control group (NC), a control group treated with Greenplast (Greenplast Q), and groups treated with the peptide of the present invention at concentrations of 1% and 2.5%. In the case of the untreated control group, the experiment was stopped about 90 seconds after the start of bleeding. [Figure 9] This is a graph showing the results of an animal experiment on the hemostatic effect of a composition containing the peptide of the present invention, comparing the bleeding loss values ​​of an untreated control group (NC), a control group treated with Greenplast (Greenplast Q), and groups treated with the peptide of the present invention at concentrations of 1% and 2.5%. In the case of the untreated control group, the bleeding loss was measured about 90 seconds after the start of bleeding. [Figure 10] 1 shows photographs and graphs comparing the results of a hemolysis test using a composition containing the peptide of the present invention. As a control group, 1% SDS and PBS were used instead of the composition of the present invention, and the results were confirmed. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The present invention will be described in detail below.

[0015] 1. Peptides with pH-dependent gelation properties One aspect of the present invention provides a novel peptide having the property of being gelled in a pH-dependent manner. In the present invention, the term "peptide" refers to a polymer of two or more amino acids linked by peptide bonds.

[0016] The term "gelation" in the present invention refers to a phenomenon in which colloidal particles in a solution are changed into a gel form (shape), and means that the colloidal particles in the solution lose fluidity and have a certain shape in a solid or semi-solid state. In general, a gel may be a gel formed by forming a chemical bond, etc., of a sol in which solid particles are dispersed in a liquid.

[0017] The peptide comprises the amino acid sequence of SEQ ID NO: 1. The peptide may include a variant peptide having a different sequence due to deletion, insertion, substitution, or a combination thereof of amino acid residues, within a range that does not affect the properties or activity of the peptide, or may be in the form of a protein fragment having the same function. Amino acid modifications at the protein and peptide level that do not overall change the properties or activity due to the inclusion of the amino acid sequence of SEQ ID NO: 1 are known in the art of the present invention, and may be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, etc., in some cases. Thus, the peptide includes not only the amino acid sequence of SEQ ID NO: 1, but also peptides having substantially the same amino acid sequence thereto or variants thereof. The peptide having substantially the same amino acid sequence may be a peptide containing an amino acid sequence having a homology of 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the amino acid sequence of SEQ ID NO: 1, but is not limited thereto. Any peptide having a sequence having an amino acid sequence with 90% or more homology to the amino acid sequence of SEQ ID NO: 1 and having the same activity is included in the scope of the present invention.

[0018] The peptide of the present invention may be one that comprises the amino acid sequence of SEQ ID NO: 1 and exhibits a property of being gelled depending on pH, and is composed of 20 or less amino acids. Specifically, the peptide may be one that comprises 20 or less, 18 or less, 15 or less, or 12 amino acids.

[0019] In addition, the peptide of the present invention can be obtained by various methods widely known in the art, including, but not limited to, preparation using polynucleotide recombination and protein expression systems, preparation in vitro through chemical synthesis such as peptide synthesis, and cell-free protein synthesis.

[0020] In addition, a protecting group may be attached to the N-terminus or C-terminus of the peptide to obtain better chemical stability, enhanced pharmacological properties (half-life, absorbency, potency, efficacy, etc.), altered specificity (e.g., broader biological activity spectrum), and reduced antigenicity. For example, the protecting group may be an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, or a polyethylene glycol (PEG), but may include any component that can enhance the modification of the peptide, particularly the stability of the peptide, without limitation. The "stability" refers not only to in vivo stability that protects the peptide of the present invention from attack by in vivo protease, but also to storage stability (e.g., room temperature storage stability).

[0021] The peptide of the present invention may be gelled at neutral pH. Specifically, the peptide may be gelled under pH conditions ranging from pH 4 to pH 8, pH 4 to pH 7, pH 4.5 to pH 7, or pH 5 to pH 7, but is not limited thereto. The peptide may be gelled in a pH range that may be exhibited by blood or body fluids of humans or non-human animals.

[0022] In addition, the peptide of the present invention may be in the form of a sol or liquid at an acidic pH. Specifically, a solution containing the peptide may be in the form of a sol or liquid at an acidic pH, for example, in the range of pH 0 to pH 3.9, and the peptide of the present invention may have a property of gelation by changing the pH to provide a neutral pH condition, losing fluidity and forming a solid or semi-solid gel.

[0023] In a specific embodiment of the present invention, the kcps value and magnitude of the light scattering intensity of the peptide were measured while changing the pH, and it was confirmed that gelation proceeded by confirming that the size of particles in the solution increased and the kcps value gradually increased under conditions of pH 4 or higher. In particular, since peptide aggregation was visually observed under conditions of pH 6 or higher, it was confirmed that the peptide of the present invention has a property of gelling depending on pH, more specifically, under neutral pH conditions.

[0024] The peptide may have the property of being gelled in the presence of a salt, for example, but not limited to, sodium chloride (NaCl). The peptide may be gelled at a salt concentration of 50 mM or more, 60 mM or more, 70 mM or more, or 100 mM or more, and the degree of gelling may increase with an increase in the salt concentration. The peptide may be gelled in a range of salt concentrations that may be present in blood or body fluids of humans or non-human animals.

[0025] In a specific embodiment of the present invention, the degree of aggregation of the peptide was visually confirmed by measuring the optical density while changing the salt concentration. As a result, it was confirmed that when the concentration of sodium chloride (NaCl) was 100 mM or more, the turbidity gradually increased, the viscosity increased, and gelation occurred.

[0026] Due to the characteristics of the peptide as described above, the peptide can induce blood coagulation. The blood coagulation means that the blood clots, and the peptide can induce a reaction in which liquid blood solidifies into a solid thrombus, clot, etc. More specifically, since the peptide has a gelling property, the nanofiber-shaped structure formed by the gelation of the peptide can induce blood cells and other blood components in the blood to surround and aggregate. Blood cells aggregated with the peptide of the present invention can form a clot, which increases in volume and can precipitate or interfere with the flow and outflow of blood. Therefore, since the peptide of the present invention has an activity of inducing blood coagulation when bleeding occurs, the peptide of the present invention or a composition containing the same can be usefully used for hemostasis.

[0027] 2. Composition for inducing hemostasis and method for hemostasis using the same Yet another aspect of the present invention provides a composition for inducing hemostasis, comprising the peptide. The peptide comprises the amino acid sequence of SEQ ID NO: 1, and the description thereof is the same as that of the peptide described in the section "1. Peptide having pH-dependent gelation properties," so the detailed description is incorporated herein by reference.

[0028] The term "hemostasis" in the present invention means reducing bleeding, which may mean reducing not only the outflow of blood but also the outflow of bodily fluids other than blood. The hemostasis is a concept that includes inducing or promoting coagulation of blood or bodily fluids, reducing the amount of bleeding, reducing the bleeding time, causing bleeding to stop, promoting the formation of a thrombus or blood clot, and the like.

[0029] The peptide of the present invention has a characteristic of gelling depending on pH, and therefore the composition containing the peptide may also be aggregated and gelled depending on pH conditions, and may be used to induce hemostasis by agglutinating with blood cells. Specifically, the peptide contained in the composition may gel at the site of bleeding, and the gel or nanofibers formed by this may aggregate while surrounding blood cells and other blood components. The aggregates thus formed may form large clumps and precipitate, or may obstruct the flow or outflow of blood. Therefore, the composition of the present invention may be useful for inducing hemostasis at the site of bleeding.

[0030] The composition may have an acidic pH, for example, a pH range of 0 to 3.9, and may be in the form of a liquid or sol that has not undergone gelation.

[0031] The peptide may be contained in the composition at a concentration of 0.5 mg / ml to 50 mg / ml. Specifically, the peptide may be contained in a concentration of 0.5 mg / ml to 50 mg / ml, 1 mg / ml to 40 mg / ml, 10 mg / ml to 35 mg / ml, or 20 mg / ml to 30 mg / ml, but is not limited thereto. When the concentration of the peptide contained in the composition of the present invention is within the above range, gelation by the peptide can be sufficiently caused, so that blood coagulation can be induced and the hemostatic effect can be sufficiently exhibited.

[0032] The composition may further include calcium ions. The calcium ions may be added to the composition of the present invention in the form of, for example, calcium chloride (CaCl2). Calcium ions are known to induce and promote blood clotting reactions in blood, and more specifically, they can be useful in the thrombin formation reaction caused by enzymes such as thrombokinase involved in blood clotting reactions. Thus, the calcium ions can be useful for the blood clotting or hemostatic effect exhibited by the composition of the present invention, and may also be included to form an appropriate salt concentration.

[0033] The composition may be capable of clotting blood at a neutral pH, more specifically, but not limited to, at pH conditions ranging from pH 4 to pH 8, pH 4 to pH 7, pH 4.5 to pH 7, or pH 5 to pH 7. The composition may be capable of clotting blood in a pH range that may be exhibited by human or non-human animal blood or body fluids.

[0034] The composition may be capable of coagulating blood at a salt concentration of 50 mM or more, more specifically, at a salt concentration of 50 mM or more, 60 mM or more, 70 mM or more, or 100 mM or more, but is not limited thereto. The composition may be capable of coagulating blood within a range of salt concentrations that may be exhibited by human or non-human animal blood or body fluids.

[0035] The composition may not cause hemolysis. The hemolysis refers to a phenomenon in which blood cells are destroyed, and specifically, may be a phenomenon in which red blood cells are destroyed. The composition of the present invention is characterized in that it does not cause hemolysis and is therefore suitable for application to blood or bleeding sites.

[0036] In a specific embodiment of the present invention, red blood cells separated from blood collected from a rat were treated with the composition of the present invention, and then centrifuged to measure the optical density of the supernatant. The measured value was significantly lower than that of the supernatant treated with 1% SDS. This is due to the absence of hemolysis of red blood cells, and it was confirmed that the composition of the present invention does not induce hemolysis of blood.

[0037] The composition may be prepared into various forms of preparations to induce hemostasis. Specifically, the composition may be in the form of at least one selected from the group consisting of powdered preparations, patches, gauze, sprays, and injections, but is not limited thereto, and may be provided in any form as long as the peptide contained in the composition can be gelled and coagulated with blood cells and other blood components.

[0038] Yet another aspect of the present invention provides a method for hemostasis using the composition. The hemostatic method of the present invention comprises a step of applying the composition according to claim 4 to a bleeding site of an animal where bleeding has occurred. The animal includes all animals, including humans and non-human animals, and the non-human animals may be, for example, cows, pigs, sheep, goats, deer, horses, rats, or poultry (chickens, ducks, geese, turkeys, ostriches, turkeys, pheasants), but are not limited thereto, and may be applied to any animal having a vascular system.

[0039] The bleeding site may include any site where blood or body fluids other than blood leak out, for example, a site where blood or body fluids leak out due to damage to the surface of the skin, a site where blood leaks out due to damage or cut in a blood vessel, a site where intestinal bleeding occurs, etc.

[0040] The method of administering the composition may vary depending on the form of the composition, for example, when the composition is a powder formulation, a spray, etc., it may be administered by spraying or applying it to the bleeding site, and when the composition is a patch, gauze, etc., it may be administered by attaching it to the surface of the bleeding site. Also, when the composition is an injection, it may be administered by injecting it into the bleeding site using a syringe, but is not limited thereto.

[0041] The hemostatic method may further include a step of applying physical pressure to the bleeding site after the step of applying the composition, but the hemostatic method of the present invention is not limited thereto, and any hemostatic method generally used to suppress bleeding may be applied together with the step of applying the composition of the present invention without any limitation.

[0042] The present invention will now be described in detail with reference to examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.

[0043] [Production example] Production of peptides Using an automatic peptide synthesizer (Milligen 9050, Millipore, USA), peptides having the amino acid sequence of SEQ ID NO: 1 shown in Table 1 below were synthesized, and these synthesized peptides were purified and separated using C18 reverse phase high performance liquid chromatography (HPLC) (Waters Associates, USA). The column used was an ACQUITY UPLC BEH300 C18 (2.1 mm x 100 mm, 1.7 μm, Waters Co, USA).

[0044] [Table 1]

[0045] [Experimental Example 1] Confirmation of peptide gelation due to pH change In order to confirm the gelation phenomenon of the peptide of the present invention having the amino acid sequence of SEQ ID NO: 1, the change in the degree of gelation was confirmed by measuring the change in the physical properties of the peptide of the present invention while adjusting the pH. Specifically, the peptide of the present invention was dissolved at a concentration of 1 mg / ml using 10 mM acetate buffer solution (pH 3.4 to pH 5.5) and 10 mM phosphate buffer solution (pH 6.0 to pH 7.4). Then, the size of the peptide was measured using a light scattering analyzer (ZetaSizer, Malvern panalytical, UK) at pH 3.4, 4, 4.5, 5, 5.5, 6, 6.5, 7, and 7.4, respectively. The size and light scattering intensity (unit: kcps) were measured.

[0046] As a result, as can be seen from FIG. 1, the kcps value of the light scattering intensity did not change significantly at pH 3.4 and 4, but the kcps value increased significantly when the pH was increased to 4.5, and it was confirmed that the gelling point, which is the pH at which gelation of the peptide of the present invention begins, is between pH 4 and pH 4.5. As the pH gradually increases, the kcps value also gradually increases, and it was measured to be the highest at pH 5.5. This is expected because the peptide of the present invention has gelling properties due to the arrangement of particles caused by the structural change induced by the increase in pH. The kcps value of the peptide was maintained high even at pH 6, and it was confirmed that aggregation of the peptide occurred by visual observation. It was shown that the particle size gradually increased as the pH increased, and it was confirmed that aggregation and gelation of the peptide occurred at neutral pH.

[0047] From the above results, it was confirmed that the peptide of the present invention has a characteristic that gelation does not proceed and aggregation phenomenon is not observed under acidic pH conditions, but gelation starts when the pH is gradually increased to pH 4 to 4.5, and aggregates to form a gel shape when the pH reaches neutral pH. Therefore, the peptide can form aggregates according to this pH condition, which can be used to induce blood coagulation, and in particular, considering the characteristic of the peptide of the present invention that gelation occurs in a pH range similar to that of animal blood and body fluids, it was confirmed that this is suitable for application to living organisms.

[0048] [Experimental Example 2] Confirmation of peptide gelation due to salt concentration In Experimental Example 1, it was confirmed that the peptide of the present invention has a property of gelling with increasing pH, and also confirmed how the gelling phenomenon of the peptide changes depending on the concentration of a salt such as NaCl. Specifically, after preparing 0, 10, 50, 100, 150 and 200 mM NaCl aqueous solutions, 100 μl of 25 mg / ml of the peptide of the present invention having the amino acid sequence of SEQ ID NO: 1 was added to 200 μl of the NaCl aqueous solutions, and mixed by vortexing at 3,500 rpm. The optical density of the mixture of the peptide and salt aqueous solution was then measured at a wavelength of 600 nm.

[0049] As a result, as can be seen from Figure 2, the turbidity of the mixture started to increase when the NaCl concentration was 100 mM, and continued to increase until the NaCl concentration reached 200 mM. This is expected to be due to the promotion of aggregation due to increased interactions between the peptide molecules of the present invention. It was also confirmed that the viscosity tended to increase up to a concentration of 150 mM NaCl.

[0050] Since a certain amount of salt is dissolved in the blood and body fluids of animals, it is necessary to confirm whether the peptide of the present invention can sufficiently gel in an environment similar to that of blood and body fluids. From the results of the gelation of the peptide according to the NaCl concentration, it was confirmed that the peptide of the present invention can be usefully used for inducing blood coagulation by forming a gel in an in vivo environment.

[0051] [Experimental Example 3] Confirmation of peptide gelation depending on peptide concentration We confirmed how the degree of gelation of the peptide of the present invention having the amino acid sequence of SEQ ID NO: 1 changes depending on the concentration of the peptide. Specifically, the peptide was dissolved in distilled water at concentrations of 5, 10, and 25 mg / ml in a 1.5 ml microtube, and then 5N NaOH was added thereto. The pH was gradually increased, and the phase transition of the mixture containing the peptide was visually observed.

[0052] As a result, as can be seen from Figure 3, the peptide of the present invention generally exhibits sol properties under initial acidic pH conditions, but gelation progresses as the pH increases. When the peptide concentration is 0.5 mg / ml, gelation does not occur even at pH 7.5 (Gelation X), but as the peptide concentration increases, peptide gelation is further promoted, and it was confirmed that gelation progressed from pH 4.2 in the tube containing the peptide at a concentration of 25 mg / ml.

[0053] [Experimental Example 4] Confirmation of hemagglutination effect of the peptide of the present invention (Hemagglutination assay) Using the peptide of the preparation example, which was confirmed to have the property of gelling and agglutinating under neutral pH conditions, it was confirmed whether or not it has an agglutinating effect on red blood cells in blood. Specifically, blood collected from a rat was divided into 1.5 ml EP tubes, centrifuged at 1,500 g for 10 minutes, the supernatant plasma was removed, and the blood was washed three times with 0.9% sodium chloride aqueous solution. Then, red blood cells and sodium chloride aqueous solution were mixed in a ratio of 3:11 (v / v) to prepare a red blood cell suspension. As a control group for the peptide of the present invention, a research-use RADA16 peptide sample (3D Matrix), which is known to have hemostatic activity and is commercially available, was used. The peptide of the preparation example of the present invention and the peptide of the control group were dissolved in purified water in a v-type 96-well plate, and 10 μl of the peptide was treated at concentrations of 0, 62.5, 125, 250, 500, and 1,000 μg / ml, respectively, and 90 μl of sodium chloride aqueous solution was added. 10 μl of the red blood cell suspension was added to the mixture, mixed at 300 rpm for 10 minutes, and reacted for 2 hours or more at 4° C. The degree of precipitation of the red blood cell suspension was then visually confirmed to evaluate the degree of blood cell aggregation due to the formation of nanofibers in each sample.

[0054] As a result, as can be seen from Figure 4, it was shown that at a peptide concentration of 500μg / ml or more, the red blood cell suspension did not precipitate but formed a thrombus. This is an effect shown by the aggregation of red blood cells by the nanofibers formed by the peptide of the present invention, and it was confirmed that the blood coagulation promoting effect was shown at a similar level to the control peptide sample, which is known to have an agglutinating effect on blood cells. Therefore, it was confirmed that the peptide of the present invention and a composition containing the same can be useful for hemostasis by inducing the aggregation of blood cells.

[0055] [Experimental Example 5] Confirmation of the blood coagulation effect of the peptide of the present invention (Blood coagulation test) In order to confirm whether the peptide of the present invention has the effect of inducing blood coagulation reaction, blood collected from rats was treated with the peptide of the present invention, and then it was confirmed whether the blood was coagulated or not.

[0056] First, the clotting time of blood treated with the peptide of the present invention was evaluated. In a state where the blood clotting reaction of a rat collected in a heparin vacuum blood collection tube was inhibited, 300 μl of blood was transferred to an EP tube and treated with 150 μl of a solution in which the peptide of the present invention was dissolved in purified water. The clotting time was measured by visually evaluating the flow of blood by turning the tube upside down at 10 second intervals. As a control group, the RADA16 peptide sample and Greenplast (Greenplast Q, GC Green Cross) were used and the experiment was carried out in the same manner as the peptide of the present invention.

[0057] As a result, as can be seen from Table 2 and Figure 5 below, when the peptide of the preparation example was treated at a concentration of 2.5%, blood was confirmed to have coagulated after 13 seconds. When Greenplast was treated, it took 20 seconds or less for blood to coagulate, and when RADA16 peptide was treated, it took 30 seconds or less. It was confirmed that the peptide of the present invention has a blood coagulation effect similar to or better than that of the commercially available preparations that have been used as hemostatic agents.

[0058] [Table 2]

[0059] In addition, to evaluate the coagulation efficacy of the peptide of the present invention, the peptide of the above Preparation Example was treated with rat blood, and its optical density was measured. Specifically, 300 μl of blood collected from a rat in a heparin vacuum blood collection tube was transferred to a 15 ml conical tube in a state where the blood coagulation reaction was inhibited, and then 300 μl of the peptide solution of the present invention was added and mixed gently. Then, 30 μl of 0.2 M CaCl2 solution was added and incubated at 37° C. for 10 minutes to promote the coagulation reaction. Next, 10 ml of distilled water was carefully added, and 200 μl of the uniformly dispersed supernatant was placed in a 96-well plate, and the optical density was measured at a wavelength of 540 nm using a spectrophotometer. Similarly, Greenplast and RADA16 peptide preparations were used as controls.

[0060] As a result, as can be seen from Figure 6, the optical density measured when the peptide of the present invention was treated was 0.41 relative to the level of blood coagulation in the negative control group treated with distilled water, and it was measured that the amount of blood cells in the supernatant was significantly reduced. This shows a blood coagulation effect that is more excellent than the effect (0.7) when treated with the RADA16 peptide preparation, a conventionally available hemostatic agent, and it was confirmed that the peptide of the present invention and a composition containing the same can be usefully used for promoting blood coagulation.

[0061] [Experimental Example 6] In vivo test of the hemostatic effect of the peptide of the present invention In order to confirm whether the blood coagulation effect of the peptide of the present invention is actually shown in animals, an animal experiment was performed. Specifically, the femoral region of 8-week-old female rats (SD-rat) was incised to expose the artery, and the exposed artery was then injured with a 21G needle to construct a bleeding model. Then, immediately after bleeding, the peptide of the present invention was dissolved in purified water and prepared at a concentration of 1% and 2.5%, and 200 μl of each sample was applied to the bleeding site, and the bleeding blood was absorbed into a gauze whose weight had been measured in advance. Then, the time required for bleeding to stop (bleeding time) was measured, and the weight of the gauze into which the blood had been absorbed was measured to confirm the bleeding loss. A Greenplast preparation was used as a positive control group, and in the case of a negative control group (No Treatment) that had not been treated, the experiment was stopped 90 seconds after bleeding began, and the bleeding loss up to that time was confirmed.

[0062] As a result, as can be seen from FIG. 7 to FIG. 9, when the peptide of the present invention was treated, the bleeding of the rats was stopped, and it was shown that the peptide had a hemostatic effect. When the peptide was treated with 1% of the present invention, the bleeding stopped after 96 seconds, and when the peptide was treated with 2.5% of the present invention, the bleeding stopped after 59 seconds, which was similar or better than the hemostatic time of the positive control group treated with Greenplast (84 seconds). When comparing the amount of blood that was bled, when the peptide of the present invention was treated with 2.5% of the present invention, the amount of bleeding was significantly reduced compared to the negative control group that was not treated and bled for 90 seconds. Therefore, it was confirmed that the peptide of the present invention showed a hemostatic effect when treated with animals that had actually bled, and could show a similar level of effect to existing commercially available hemostatic agents.

[0063] [Experimental Example 7] Confirmation of the occurrence of hemolysis due to the peptide of the present invention (Hemolysis test)

[0064] Furthermore, it was confirmed whether or not hemolysis, in which blood cells are destroyed, occurs due to the peptide treatment of the present invention. The blood of rats collected in heparin vacuum blood collection tubes was transferred to EP tubes in a state in which the blood coagulation reaction was inhibited, and centrifuged at 1,500 g for 10 minutes. After removing the supernatant plasma, the precipitated red blood cells were treated with 200 μl each of 2.5% and 5% of the peptide of the present invention. As a positive control for hemolysis, samples treated with 1% SDS were used. Each sample was stored in a 37°C incubator for 1 hour, and then centrifuged again at 1,500 g for 10 minutes. 200 μl of the supernatant was transferred to a 96-well plate, and the optical density was measured at a wavelength of 540 nm.

[0065] As a result, as can be seen from Figure 10, hemolysis occurred in the group treated with SDS, but the peptide of the present invention did not induce hemolysis at either 2.5% or 5% concentration, similar to the negative control group. Therefore, it was confirmed that the peptide of the present invention does not destroy blood cells, so there is no problem in using it for the purpose of inducing blood coagulation, and it was confirmed that a composition containing the peptide can be useful for hemostasis.

[0066] Although the present invention has been described in detail above only with respect to the described embodiments, it will be apparent to those skilled in the art that various modifications and variations are possible within the scope of the technical concept of the present invention, and it is natural that such modifications and variations fall within the scope of the claims.

Claims

1. A peptide having pH-dependent gelation properties, consisting of the amino acid sequence of SEQ ID NO:

1.

2. The peptide of claim 1 , wherein the peptide is gelled at a pH of 4 to 8.

3. The peptide of claim 1 , wherein the peptide is capable of inducing blood clotting.

4. A composition for inducing hemostasis comprising the peptide of claim 1.

5. 5. The composition for inducing hemostasis according to claim 4, wherein the peptide is present in the composition at a concentration of 0.5 mg / ml to 50 mg / ml.

6. The composition for inducing hemostasis according to claim 4 , further comprising calcium ions.

7. 5. The composition for inducing hemostasis according to claim 4, wherein the composition causes blood to clot at a pH between 4 and 8.

8. The composition for inducing hemostasis according to claim 4 , which coagulates blood under conditions where the salt concentration is 50 mM or more.

9. The composition for inducing hemostasis according to claim 4 , wherein the composition does not cause hemolysis.

10. The composition for inducing hemostasis according to claim 4, wherein the composition is in at least one form selected from the group consisting of a powder formulation, a patch, a gauze, a spray and an injection.

11. 10. A method of hemostasis comprising the step of applying the composition of claim 4 to the site of bleeding in a non-human animal where bleeding has occurred.

Images